#obesity-drugs

[ follow ]
#bankruptcy
Wellness
fromNew York Post
3 days ago

WeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs

WW International has filed for Chapter 11 bankruptcy due to rising competition from obesity drugs that undermined its traditional business model.
fromwww.cbc.ca
2 days ago
Wellness

WeightWatchers files for bankruptcy after weight-loss drugs capsized industry | CBC News

WW International has filed for Chapter 11 bankruptcy to reduce its debt due to competition from new obesity medications.
Wellness
fromNew York Post
3 days ago

WeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs

WW International has filed for Chapter 11 bankruptcy due to rising competition from obesity drugs that undermined its traditional business model.
fromwww.cbc.ca
2 days ago
Wellness

WeightWatchers files for bankruptcy after weight-loss drugs capsized industry | CBC News

WW International has filed for Chapter 11 bankruptcy to reduce its debt due to competition from new obesity medications.
more#bankruptcy
Digital life
fromwww.nytimes.com
3 months ago

Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

Novo Nordisk reported strong earnings in 2024 but expects slower sales growth in 2025 due to competition.
The company’s share price has fallen dramatically amid uncertainties in the obesity drug market.
Medicine
fromNature
3 months ago

Obesity drugs: huge study highlights new health risks

GLP-1 receptor agonists have significant benefits for weight loss and other conditions but also present risks like arthritis and pancreatitis.
Medicine
fromwww.npr.org
4 months ago

Consultations for obesity drug prescriptions are way up over 2023, survey finds

The demand for consultations about obesity drugs is surging, particularly influenced by social factors and public figures.
fromFast Company
7 months ago
Medicine

Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over

Hims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.
[ Load more ]